UK consortia brings together internationally recognized investigators in the UK's leading centers of excellence to carry out experimental and early phase research Translational work to be conducted will provide GRI Bio additional data examining the role of NKT cells in idiopathic pulmonary fibrosis (“IPF”) from patients across the UK GRI Bio rapidly advancing lead program, GRI-0621 a type 1 invariant NKT (“iNKT“) antagonist in development for the treatment of IPF LA JOLLA, CA, Oct.

英国财团汇集了英国领先的卓越中心的国际公认的研究人员，开展实验和早期研究。将进行的转化工作将提供GRI-Bio额外的数据，检查NKT细胞在特发性肺纤维化（“IPF”）中的作用来自英国GRI-Bio快速推进的铅项目的患者，GRI-0621 1型不变NKT（“iNKT”）拮抗剂正在开发中，用于治疗IPF LA JOLLA，CA，Oct。

17, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced it has entered into a collaboration with the UK consortia, National Institute for Health and Care Research Respiratory Translational Research Collaboration (“NIHR Respiratory TRC”) to advance its leading NKT regulation technology to treat inflammatory, fibrotic and autoimmune diseases.

172023（GLOBE NEWSWIRE）-GRI Bio，Inc。（纳斯达克股票代码：GRI）（“GRI Bio”或“公司”），一家生物技术公司，推进创新的自然杀伤T（“NKT”）细胞管道今天宣布它已与英国财团合作，美国国立卫生研究院呼吸转化研究合作组织（“NIHR Respiratory TRC”）推进其领先的NKT调节技术，以治疗炎症，纤维化和自身免疫性疾病。

IPF is a rare chronic progressive pulmonary disease with abnormal scarring of the lung blocking the movement of oxygen into the bloodstream. GRI Bio’s lead program, GRI-0621 is a small molecule RAR-βɣ dual agonist that inhibits the activity of human type 1, iNKT cells. In preliminary trials to date1 and previous trials with the oral formulation, GRI-0621 has been shown to improve fibrosis in multiple disease models and improve liver function tests and other markers of inflammation and injury in patients.

IPF是一种罕见的慢性进行性肺部疾病，肺部瘢痕形成异常，阻止氧气进入血液。GRI Bio的牵头项目GRI-0621是一种小分子RAR-βɣ双重激动剂，可抑制人类1型iNKT细胞的活性。在迄今为止的初步试验1和之前的口服制剂试验中，GRI-0621已被证明可改善多种疾病模型中的纤维化，并改善肝功能检查和患者炎症和损伤的其他标志物。

Together with the NIHR Respiratory TRC, GRI Bio will design and execute complex multi-center studies that accelerate research for the benefit of respiratory disease patients.  “As a Company, we are dedicated to revolutionizing the way that .

GRI Bio将与NIHR Respiratory TRC一起设计和执行复杂的多中心研究，加速研究，为呼吸系统疾病患者带来益处。“作为一家公司，我们致力于彻底改变这种方式。